Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2009-09-27 AGM Information
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting/Proxy Form 43 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING, EXPLANATORY MEMORANDUM AND PROXY FORM' for HalcyGen Pharmaceuticals Limited, dated for a meeting on 28 October 2009. It includes detailed agenda items typical of an AGM notice: re-election of directors, ratification and approval of share placements, approval of share options, adoption of remuneration report, and financial assistance resolutions. The document is a notice and explanatory memorandum for the AGM, not the actual annual report or financial statements. It contains proxy forms and voting exclusion statements, which are typical for AGM notices. The document length is about 15,000 characters, which is consistent with a detailed AGM notice and explanatory memorandum. There is no indication that this is the full annual report or financial statements, but rather the meeting notice and related explanatory materials. Therefore, the document fits the category of AGM Information (AGM-R).
2009-09-27 English
Annual Report to shareholders 60 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2009' and contains extensive sections typical of an annual report, including a Chairman's Letter, CEO and Operations Review, Directors' Report, Auditor's Independence Declaration, Corporate Governance Statement, Income Statement, Balance Sheet, Cash Flow Statement, Notes to the Financial Statements, Directors' Declaration, and Independent Auditor's Report. The content includes detailed company strategy, product development, regulatory and clinical development updates, and financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is merely an announcement of a report or a certification document. Therefore, this document fits the definition of an Annual Report (10-K equivalent).
2009-09-27 English
Company Presentation - Update 16 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed presentation from HalcyGen Pharmaceuticals Limited dated September 2009. It includes an overview of the company, acquisition details of Mayne Pharma International, pro forma financials, capital structure, acquisition rationale, and operational details of the acquired company and its facilities. The content is structured as a presentation with slides, including financial forecasts, strategic rationale, and operational descriptions. There is no indication that this is a formal regulatory filing like an annual report or audit report, nor is it a transcript or voting result. The document is clearly a detailed investor presentation focusing on financials, strategy, and market position related to an acquisition and company overview. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2009-09-27 English
Section 708A Cleansing Notice 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001, indicating the issuance of shares via a private placement without disclosure under Part 6D.2 of the Act. It details the number of shares issued, the purpose of the placement, and compliance with relevant sections of the Act. The document is short (1558 characters) and serves as a formal regulatory announcement about a capital raising event rather than a full financial report or detailed financing update. Given the nature of the notice, it fits best under Capital/Financing Update (CAP) as it relates to fundraising activities and capital structure changes.
2009-09-27 English
HalcyGen SPP 7 October 2009 6 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a detailed offer to shareholders for participation in a Share Purchase Plan (SPP) by HalcyGen Pharmaceuticals Limited. It includes terms and conditions, eligibility criteria, pricing, application instructions, and details about the acquisition financing. The document is not a financial report, earnings release, or management discussion. It is an announcement and offer related to a capital raising activity through a share purchase plan, including underwriting and shareholder approval details. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length and content confirm it is not a brief announcement or a report publication notice but a substantive offer document.
2009-09-27 English
HalcyGen Acquires Mayne Pharma International from Hospira 4 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding HalcyGen's acquisition of a wholly owned subsidiary of Hospira Inc. It details the terms of the acquisition, financial expectations, financing arrangements including loans and share placements, and strategic rationale. The content focuses on the transaction details, financing plans, and business implications rather than presenting financial statements or detailed financial performance data. There is no indication that this is a full financial report, earnings release, or regulatory filing of financial results. The document is primarily an announcement of a merger/acquisition transaction and related financing activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP), as it includes updates on company fundraising and capital structure changes related to the acquisition.
2009-09-24 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.